Mostrar el registro sencillo del documento

Evaluación de herramientas diagnósticas de cardiotoxicidad en pacientes tratados con quimioterapia

dc.rights.licenseAtribución-NoComercial-SinDerivadas 4.0 Internacional
dc.contributor.advisorMéndez Toro, Arnold
dc.contributor.advisorTejada, Rafael
dc.contributor.authorMuñoz Rossi, Felipe Alejandro
dc.date.accessioned2021-07-07T19:05:12Z
dc.date.available2021-07-07T19:05:12Z
dc.date.issued2020
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/79768
dc.descriptionilustraciones, tablas
dc.description.abstractEl cáncer es un evento en salud catastrófico, siendo actualmente la segunda causa de muerte en América latina y en Colombia, Por lo tanto, es un problema de salud pública que no debe pasar desapercibido. Como parte de los efectos colaterales del tratamiento contra el cáncer, uno de los que presenta mayores repercusiones es el desarrollo de eventos cardiovasculares aumentando la morbimortalidad en los pacientes con cáncer. Dada la relevancia de la cardiotoxicidad, es importante identificarla y efectuar el control de la presencia de esta en los pacientes con quimioterapia, lo cual ha llevado al desarrollo de programas que mediante un abordaje estructurado que congrega a varias especialidades con el fin de categorizar según el perfil de riesgo individualizado una serie de estrategias diagnósticas preventivas y terapéuticas que permitan minimizar el daño derivado de la terapia antineoplásica. De acuerdo con lo anterior, el objetivo del estudio es evaluar el uso de herramientas diagnósticas para la vigilancia de la aparición de cardiotoxicidad en una población adulta con cáncer, bajo tratamiento antineoplásico clasificado como de riesgo intermedio, alto o muy alto de acuerdo a la clasificación de Mayo Clinic Cardiotoxicity Risk, en el Hospital Universitario Nacional de Colombia atendidos entre los años 2016 y 2019. (Texto tomado de la fuente)
dc.description.abstractCancer is a catastrophic health event, being currently the second cause of death in Latin America and Colombia. Therefore, it is a public health problem that should not go unnoticed. As part of the collateral effects of cancer treatment, one of those with the greatest repercussions is the development of cardiovascular events, increasing morbidity and mortality in cancer patients. Given the relevance of cardiotoxicity, it is important to identify it and control its presence in patients with chemotherapy, which has led to the development of programs that, through a structured approach that brings together several specialties in order to categorize according to the individualized risk profile a series of preventive and therapeutic diagnostic strategies that allow minimizing the damage derived from antineoplastic therapy. In accordance with the above, the objective of the study is to evaluate the use of diagnostic tools for the surveillance of the appearance of cardiotoxicity in an adult population with cancer, under antineoplastic treatment classified as intermediate, high or very high risk according to the classification from Mayo Clinic Cardiotoxicity Risk, at the National University Hospital of Colombia attended between 2016 and 2019. (Text taken from source)
dc.format.extent76 páginas
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.publisherUniversidad Nacional de Colombia
dc.rightsDerechos Reservados al Autor, 2021
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc610 - Medicina y salud
dc.titleEvaluación de herramientas diagnósticas de cardiotoxicidad en pacientes tratados con quimioterapia
dc.typeTrabajo de grado - Especialidad Médica
dcterms.audienceGeneral
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.publisher.programBogotá - Medicina - Especialidad en Medicina Interna
dc.contributor.datamanagerRojas Ruiz, Ingrid Tatiana
dc.description.degreelevelEspecialidades Médicas
dc.description.degreenameEspecialista en Medicina interna
dc.identifier.instnameUniversidad Nacional de Colombia
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourlhttps://repositorio.unal.edu.co/
dc.publisher.departmentDepartamento de Medicina Interna
dc.publisher.facultyFacultad de Administración
dc.publisher.placeBogotá, Colombia
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.relation.references1. INC-Instituto Nacional de Cancerología. Atlas de Mortalidad [Internet]. Bogotá; 2017. Available from: cancer.gov.co/ATLAS_de_Mortalidad_por_cancer_en_Colombia.pdf
dc.relation.references2. Jaramillo, N. Gónzalez, M., Berrouet, M.C. & Velasquez C. Cardiotoxicidad inducida por la quimioterapia desde las bases moleculares hasta la perspectiva clínica. Rev Col Card. 2016;23(2):104–11.
dc.relation.references3. Curigliano, G., Cardinale, D., Dent, S. et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309–25.
dc.relation.references4. P. Spallarossa, N. Maurea, C. Cadeddu et al. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2016;17:84–92.
dc.relation.references5. N. Maurea, P. Spallarossa, C. Cadeddu et al. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2016;17:93–104.
dc.relation.references6. R. Madonna, C. Cadeddu, M. Deidda et al. Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology. Int J Cardiol. 2015;191:203–10.
dc.relation.references7. Z.V. Varga, Z. Giricz, P. Bencsik et al. Functional genomics of cardioprotection by ischemic conditioning and the influence of comorbid conditions: Implications in target identification. Curr Drug Targets. 2015;16:904–11.
dc.relation.references8. López-Fernández, T., Saura, D., Rodríguez-Palomares, J., Aguadé-Bruix, S., Pérez de Isla, L. & Barba-Cosials J. Cardiac imaging 2015: A selection of topical issues. Rev Esp Cardiol. 2016;69:286–93.
dc.relation.references9. J.C. Plana, M. Galderisi, A. Barac et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr,. 2014;27:911–39.
dc.relation.references10. Madonna R. Diagnóstico y prevención de la cardiotoxicidad inducida por fármacos antineoplásicos: de la imagen a las tecnologías «ómicas». Rev Esp Cardiol. 2017;70(7):576–82.
dc.relation.references11. World Health Organization. Globocan 2012: Estimated Cancer incidence, mortality and prevalence worldwide. Lyon; 2012.
dc.relation.references12. Florescu, M., Cinteza, M. & Vinereanu D. Chemotherapy-induced Cardiotoxicity. Mædica. 2013;8(1):59–67.
dc.relation.references13. Figueredo, V.M. & Chemical C. The Negative Effects of Medications and Nonprescribed Drugs on the Heart. Am J Med. 2011;124(6):480–8.
dc.relation.references14. DeSantis, C.E., Lin, C.C., Mariotto, A.B., Siegel, R.L., Stein, K.D. K, J.L. et al. Cancer treatment and survivorship statistics, 2014: Cancer Treatment and Survivorship Statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.
dc.relation.references15. Ruiz, E., Ayala, L., Burgos J. Insuficiencia Cardiaca por quimioterapia. Rev Soc Per Med Int. 2016;29(2):59–64.
dc.relation.references16. Perrino, C., Schiattarella, G., Magliulo, F., Ilardi, F., Carotenuto, G., Gargiulo, G. et al. Cardiac side effects of chemotherapy: state of art and strategies for a correct management. Curr Vasc Pharm. 2014;12(1):106–16.
dc.relation.references17. Bloom, M., Hamo, C., Cardinale, D., Ky, B., Nohria, A., Baer, L. E, Al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure. Circ Hear Fail. 2016;9(2):e002843.
dc.relation.references18. Bovelli, D., Plataniotis, G., Roila, F. O behalf of the EGWG. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Supplement 5):277–82.
dc.relation.references19. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.
dc.relation.references20. Jiji, R.S., Kramer CM& SM. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol. 2012;19(2):377–88.
dc.relation.references21. Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora S&, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14–25.
dc.relation.references22. Siegel, R.L., Miller, K.D. & Jemal A. Cancer statistics, 2015: Cancer Statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
dc.relation.references23. Ministerio de Salud P. Análisis de la situación del cáncer en el Perú 2013. Lima; 2013.
dc.relation.references24. Minsalud. Observatorio Nacional de Cáncer [Internet]. Dirección de Epidemiología y Prevención. D de P y P& S de E no T, editor. Bogotá: Minsalud; 2018. 9–10 p. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/GCFI/guia-ross-cancer.pdf
dc.relation.references25. Virizuela JA, García AM, de las Peñas R, Santaballa A, Andrés R, Beato C, et al. SEOM clinical guidelines on cardiovascular toxicity (2018). Clin Transl Oncol. 2019;21(1):94–105.
dc.relation.references26. Alvarez JA, Russell RR. Cardio-oncology: the Nuclear Option. Vol. 19, Current Cardiology Reports. Current Medicine Group LLC 1; 2017.
dc.relation.references27. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37(36):2768–801.
dc.relation.references28. Tamargo J, Caballero R, Delpón E. Cancer Chemotherapy and Cardiac Arrhythmias: A Review. Vol. 38, Drug Safety. Springer International Publishing; 2015. p. 129–52.
dc.relation.references29. Kappel C, Rushton M, Johnson C, Aseyev O, Small G, Law A, et al. Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: An observational cohort study. Curr Oncol. 2019;26(3):e322–7.
dc.relation.references30. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar;344(11):783–92.
dc.relation.references31. Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. Clin Med Insights Cardiol. 2019 Jan;13:117954681986644.
dc.relation.references32. Zhang X, Zhu Y, Dong S, Zhang A, Lu Y, Li Y, et al. Role of oxidative stress in cardiotoxicity of antineoplastic drugs. Vol. 232, Life Sciences. Elsevier Inc.; 2019.
dc.relation.references33. Almuwaqqat Z, Meisel JL, Barac A, Parashar S. Breast Cancer and Heart Failure. Vol. 15, Heart Failure Clinics. Elsevier Inc.; 2019. p. 65–75.
dc.relation.references34. Limat S, Daguindau E, Cahn JY, Nerich V, Brion A, Perrin S, et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin’s lymphoma. J Clin Pharm Ther. 2014;39(2):168–74.
dc.relation.references35. Accordino MK, Neugut AI, Hershman DL. Cardiac effects of anticancer therapy in the elderly. Vol. 32, Journal of Clinical Oncology. American Society of Clinical Oncology; 2014. p. 2654–61.
dc.relation.references36. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003 Jun;97(11):2869–79.
dc.relation.references37. Armenian S, Bhatia S. Predicting and Preventing Anthracycline-Related Cardiotoxicity. Am Soc Clin Oncol Educ B. 2018 May;(38):3–12.
dc.relation.references38. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991 Sep;266(12):1672–7.
dc.relation.references39. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015 Jun;131(22):1981–8.
dc.relation.references40. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: Cardio-oncology. Mayo Clin Proc. 2014;89(9):1287–306.
dc.relation.references41. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: A prospective evaluation of new dosing regimens. J Clin Oncol. 1991;9(7):1215–23.
dc.relation.references42. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981 May;141(6):758–63.
dc.relation.references43. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan;14(1):72–80.
dc.relation.references44. Sendur MAN, Aksoy S, Altundag K. Cardiotoxicity of novel HER2-targeted therapies. Vol. 29, Current Medical Research and Opinion. 2013. p. 1015–24.
dc.relation.references45. Dokmanovic M, King KE, Mohan N, Endo Y, Wu WJ. Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab. Vol. 13, Expert Opinion on Drug Metabolism and Toxicology. Taylor and Francis Ltd; 2017. p. 755–66.
dc.relation.references46. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Vol. 12, Nature Reviews Cardiology. Nature Publishing Group; 2015. p. 547–58.
dc.relation.references47. Onitilo AA, Engel JM, Stankowski R V. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: Prevalence, patient characteristics, and risk factors. Vol. 5, Therapeutic Advances in Drug Safety. 2014. p. 154–66.
dc.relation.references48. Armenian SH, Lacchetti C, Barac A. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 35:893–911.
dc.relation.references49. Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: Preventive strategies and cardiovascular surveillance. Vol. 13, Vascular Health and Risk Management. Dove Medical Press Ltd.; 2017. p. 293–303.
dc.relation.references50. Lee WS, Kim J. Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy. Vol. 14, Molecular and Cellular Toxicology. Springer Verlag; 2018. p. 247–54.
dc.relation.references51. Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular toxicity in cancer. Circulation. 2018;137(11):1176–91.
dc.relation.references52. Groarke JD, Choueiri TK, Slosky D, Cheng S, Moslehi J. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway. Vol. 16, Current Treatment Options in Cardiovascular Medicine. Springer Healthcare; 2014.
dc.relation.references53. Cole DC, Frishman WH. Cardiovascular complications of proteasome inhibitors used in multiple myeloma. Vol. 26, Cardiology in Review. Lippincott Williams and Wilkins; 2018. p. 122–9.
dc.relation.references54. Meseeha MG, Kolade VO, Attia MN. Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy. J Community Hosp Intern Med Perspect. 2015 Jan;5(6):28982.
dc.relation.references55. Reneau JC, Asante D, van Houten H, Sangaralingham LR, Buadi FK, Lerman A, et al. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients. Vol. 92, American Journal of Hematology. Wiley-Liss Inc.; 2017. p. E15–7.
dc.relation.references56. Chow EJ, Chen Y, Kremer LC, Breslow NE, Hudson MM, Armstrong GT, et al. Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol. 2015 Feb;33(5):394–402.
dc.relation.references57. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014 Feb;3(1):e000472.
dc.relation.references58. Cardinale DM, Barac A, Torbicki A, Khandheria BK, Lenihan D, Minotti G. Cardio-oncological management of patients. Semin Oncol. 2019 Dec;46(6):408–13.
dc.relation.references59. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018 May;94:126–37.
dc.relation.references60. Advani PP, Ballman K V, Dockter TJ, Colon-Otero G, Perez EA. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol. 2016 Feb;34(6):581–7.
dc.relation.references61. Suter TM, Procter M, Van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007 Sep;25(25):3859–65.
dc.relation.references62. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010 Sep;28(25):3910–6.
dc.relation.references63. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A MT. Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy: A Systematic Review - PubMed. J Am Coll Cardiol. 2014;1(63):2751–8. 64. Kenigsberg B, Wellstein A, Barac A. Left Ventricular Dysfunction in Cancer Treatment. JACC Hear Fail. 2018;6(2).
dc.relation.references65. Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. J Am Coll Cardiol HF. 1:72–8.
dc.relation.references66. Boffa RJ, Constanti M, Floyd CN, Wierzbicki AS. Hypertension in adults: Summary of updated NICE guidance. BMJ. 2019;367(October):1–6.
dc.relation.references67. Milan A, Puglisi E, Ferrari L, Bruno G, Losano I, Veglio F. Arterial hypertension and cancer. Vol. 134, International Journal of Cancer. Wiley-Liss Inc.; 2014. p. 2269–77.
dc.relation.references68. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for themanagement of arterial hypertension. Vol. 39, European Heart Journal. Oxford University Press; 2018. p. 3021–104.
dc.relation.references69. Schlitt A, Jordan K, Vordermark K, Schwamborn J, Langer T TC. Cardiotoxicity and oncological treatments. Dtsch Ärztebl Int. 2014;111:161–8.
dc.relation.references70. Reagan WJ, York M, Berridge B, Schultze E, Walker D PS. Comparison of Cardiac Troponin I and T, Including the Evaluation of an Ultrasensitive Assay, as Indicators of Doxorubicin-induced Cardiotoxicity. Toxicol Pathol. 2013;41:1146–58.
dc.relation.references71. Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T TM. Troponins and Brain Natriuretic Peptides for the Prediction of Cardiotoxicity in Cancer Patients: A Meta-Analysis. Eur J Hear Fail. 2020;22(2):350–61.
dc.relation.references72. Velasquez CA, González M, Berrouet MC JN. Cardiotoxicidad inducida por la quimioterapia desde las bases moleculares hasta la perspectiva clínica. Rev Col Card. 2016;23(3):104–11.
dc.relation.references73. Dogru A, Cabuk D, Sahin T, Dolasik I, Temiz S UK. Evaluation of Cardiotoxicity via Speckle-Tracking Echocardiography in Patients Treated with Anthracyclines. Oncol Res Treat. 2013;36(712–716).
dc.relation.references74. Seo JM, Park TH, Lee DY et al. Subclinical myocardial dysfunction in metabolic syndrome patients without hypertension. J Cardiiovasc Ultrasound. 2011;19:134–9.
dc.relation.references75. Stanton T, Leano R MT. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging. 2009;2:356–64.
dc.relation.references76. Thavendiranathan P, Negishi T, Somerset E, Negishi K et al. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. 2020;
dc.relation.references77. Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P et al. The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a Position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the. J Hear Fail. 2020;
dc.relation.references78. Ruiz Mori E, Ayala Bustamante L BBJ. Insuficiencia cardíaca por quimioterapia. Rev Soc Per Med Int. 2016;29(2):59–64.
dc.relation.references79. Marty M, Cognetti F, Maraninchi D, Snyder R ML. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265.
dc.relation.references80. KR. C. Herceptin and the heart a molecular modifier of cardiac failure. NEJM. 2006;354:789–90.
dc.relation.references81. Navarrete S, Castellanos A SC. Cardiotoxicidad por quimioterapia: Enfoque práctico para el clínico. Insuf Card. 2011;6(3):131–43.
dc.relation.references82. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;105(25):3122.
dc.relation.references83. Bonow RO, Bennett S, Casey DE, Ganiats TG, Hlatky MA, Konstam MA et al. A. Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): e. Circulation. 2005;112(12):1853–67.
dc.relation.references84. Yeh ET BC. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.
dc.relation.references85. Jiménez-Cotes EA, Meyer-Martínez WS G-GD. Biomarcadores en la detección temprana de cardiotoxicidad inducida por quimioterapia; estado actual. Arch Med. 2015;15(1):126–37.
dc.relation.references86. López-Velarde Peña T L-VBP. Prevención y tratamiento de cardiotoxicidad en pacientes con cáncer. An Med. 2014;59(1):54–60.
dc.relation.references87. Lax J, Piñeiro D, Falconi M, Agüero R, Barugel M, Bermann A et al. Consenso de diagnóstico, prevención y tratamiento de la cardiotoxicidad por tratamiento médico del cáncer. Rev Arg Cardiol. 2013;81(5):1–64.
dc.relation.references88. Reborido N, Parma G, Noria S, Schiavone A, Bonelli A LR. Strain bidimensional para detección precoz de disfunción sistólica del ventrículo izquierdo inducida por agentes quimioterápicos. Rev Urug Card. 2016;31(2):266–76.
dc.relation.references89. Navarro-Ulloa OD, Barranco-Camargo LA, Jurado-López SP, Zabala-Carballo CI G-P LE. Muerte súbita debida a cardiotoxicidad aguda inducida por antraciclinas. Rev Col Card. 2018;25(1):1–7.
dc.relation.references90. Gutiérrez-Alba G, González-Block MÁ R-MH. Desafíos en la implantación de guías de práctica clínica en instituciones públicas de México: estudio de casos múltiple. Sal Pub Mex. 2015;57(6):547–54.
dc.relation.references91. Kenefick H, Lee J F V. Improving physician adherence to clinical practice guidelines barriers and strategies for change. New Engl Heal Inst. 2008;55.
dc.relation.references92. Constantino-Casas P, Medécigo-Micete C, Millán-Gámez YYK, Torres-Arreola LDPL, Valenzuela-Flores AA, Viniegra-Osorio A et al. Survey on physicians’ knowledge and attitudes towards clinical practice guidelines at the Mexican Institute of Social Security. Eval Clin Pr. 2011;17(4):768–74.
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.subject.decsDrug-Related Side Effects and Adverse Reactions
dc.subject.decsEfectos Colaterales y Reacciones Adversas Relacionados con Medicamentos
dc.subject.decsQuimioterapia
dc.subject.decsChemotherapy
dc.subject.proposalCardiotoxicidad
dc.subject.proposalCáncer
dc.subject.proposalAntraciclinas
dc.subject.proposalCardiotoxicity
dc.subject.proposalCancer
dc.subject.proposalAnthracyclines
dc.title.translatedEvaluation of diagnostic tools for cardiotoxicity in patients treated with chemotherapy
dc.type.coarhttp://purl.org/coar/resource_type/c_46ec
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2


Archivos en el documento

Thumbnail
Nombre:
72292127.2021.pdf
Tamaño:
2.265Mb
Formato:
PDF
Descripción:
Tesis de Especialidad en Medicina ...
Descargar
Thumbnail
Nombre:
license_rdf
Tamaño:
805bytes
Formato:
application/rdf+xml
Descargar

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento

Atribución-NoComercial-SinDerivadas 4.0 InternacionalEsta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial 4.0.Este documento ha sido depositado por parte de el(los) autor(es) bajo la siguiente constancia de depósito